{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:07:18Z","timestamp":1769605638300,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.lfs.2020.119014","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T01:42:23Z","timestamp":1609724543000},"page":"119014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Safe and low-dose but therapeutically effective adenovirus-mediated hepatocyte growth factor gene therapy for type 1 diabetes in mice"],"prefix":"10.1016","volume":"268","author":[{"given":"Eriko","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Obama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichiro","family":"Kosai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2020.119014_bb0005","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.119014_bb0010","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(19)31334-0","article-title":"Advances in \u03b2-cell replacement therapy for the treatment of type 1 diabetes","volume":"394","author":"Vantyghem","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.119014_bb0015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2337\/dc17-1779","article-title":"Improved health-related quality of life in a phase 3 islet transplantation trial in type 1 diabetes complicated by severe hypoglycemia","volume":"41","author":"Foster","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2020.119014_bb0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/342440a0","article-title":"Molecular cloning and expression of human hepatocyte growth factor","volume":"342","author":"Nakamura","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2020.119014_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-9-55","article-title":"Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I\/II clinical trial, following preclinical studies to ensure safety","volume":"9","author":"Ido","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lfs.2020.119014_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hep.510300102","article-title":"Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice","volume":"30","author":"Kosai","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.lfs.2020.119014_bb0035","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1006\/bbrc.1998.8293","article-title":"Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor","volume":"244","author":"Kosai","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2020.119014_bb0040","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1161\/01.CIR.0000065579.19126.B8","article-title":"Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice","volume":"107","author":"Li","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2020.119014_bb0045","first-page":"8563","article-title":"Dynamic expression and localization of c-MET isoforms in the developing rat pancreas","volume":"7","author":"Wu","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.lfs.2020.119014_bb0050","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2337\/db09-1305","article-title":"Disruption of hepatocyte growth factor\/c-Met signaling enhances pancreatic beta-cell death and accelerates the onset of diabetes","volume":"60","author":"Mellado-Gil","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2020.119014_bb0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9440(10)62987-2","article-title":"Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance","volume":"167","author":"Dai","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lfs.2020.119014_bb0060","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.2337\/diabetes.54.7.2090","article-title":"Targeted inactivation of hepatocyte growth factor receptor c-met in beta-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of beta-cell mass","volume":"54","author":"Roccisana","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2020.119014_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2019.107502","article-title":"The approved gene therapy drugs worldwide: from 1998 to 2019","volume":"40","author":"Ma","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.lfs.2020.119014_bb0070","doi-asserted-by":"crossref","first-page":"27080","DOI":"10.1074\/jbc.M211947200","article-title":"Hepatocyte growth factor preserves beta cell mass and mitigates hyperglycemia in streptozotocin-induced diabetic mice","volume":"278","author":"Dai","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2020.119014_bb0075","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00125-011-2070-3","article-title":"In vivo genetic engineering of murine pancreatic beta cells mediated by single-stranded adeno-associated viral vectors of serotypes 6, 8 and 9","volume":"54","author":"Jimenez","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2020.119014_bb0080","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/emm.2003.64","article-title":"Adenoviral mediated hepatocyte growth factor gene attenuates hyperglycemia and beta cell destruction in overt diabetic mice","volume":"35","author":"Park","year":"2003","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lfs.2020.119014_bb0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.lfs.2020.119014_bb0090","author":"Audentes Therapeutics"},{"key":"10.1016\/j.lfs.2020.119014_bb0095","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving forward after two deaths in a gene therapy trial of myotubular myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.lfs.2020.119014_bb0100","author":"Audentes Therapeutics"},{"key":"10.1016\/j.lfs.2020.119014_bb0105","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3892\/ijmm.2016.2784","article-title":"Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms","volume":"38","author":"Sakamoto","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.lfs.2020.119014_bb0110","first-page":"77","article-title":"Adenoviral gene transduction of hepatocyte growth factor elicits inhibitory effects for hepatoma","volume":"27","author":"Yuge","year":"2005","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lfs.2020.119014_bb0115","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2337\/db09-1771","article-title":"Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes","volume":"59","author":"Zauli","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2020.119014_bb0120","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2005.10.027","article-title":"In vivo hepatic HB-EGF gene transduction inhibits Fas-induced liver injury and induces liver regeneration in mice: a comparative study to HGF","volume":"44","author":"Khai","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.lfs.2020.119014_bb0125","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3892\/ijmm.2014.1686","article-title":"Intramuscular injection of adenoviral hepatocyte growth factor at a distal site ameliorates dextran sodium sulfate-induced colitis in mice","volume":"33","author":"Yuge","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.lfs.2020.119014_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1382-6689(00)00064-8","article-title":"Characterization of low dose streptozotocin-induced progressive diabetes in mice","volume":"9","author":"Ito","year":"2001","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.lfs.2020.119014_bb0135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.gtc.2019.02.005","article-title":"Next generation of adeno-associated virus vectors for gene therapy for human liver diseases","volume":"48","author":"Berns","year":"2019","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"10.1016\/j.lfs.2020.119014_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107453","article-title":"Adeno-associated viral vector-mediated immune responses: understanding barriers to gene delivery","volume":"207","author":"Nidetz","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2020.119014_bb0145","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1073\/pnas.94.2.701","article-title":"Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor\/scatter factor","volume":"94","author":"Takayama","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520317744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520317744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:37:04Z","timestamp":1758400624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520317744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":29,"alternative-id":["S0024320520317744"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.119014","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safe and low-dose but therapeutically effective adenovirus-mediated hepatocyte growth factor gene therapy for type 1 diabetes in mice","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.119014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"119014"}}